– USA, CA – NuGene (OTCBB:NUGN) today announced that it has appointed Ted Schwarz to their Board of Directors effective June 13, 2016. Mr. Schwarz previously served as President of SkinMedica, a leading topical medical aesthetics company. During his nine years at SkinMedica he directed the commercial, new product and R&D teams allowing for seven straight years of market leading growth positioning SkinMedica for its successful acquisition by pharmaceutical giant Allergan for $350MM.
Schwarz said, “I am honored and delighted to join NuGene’s Board of Directors, one of the premier emerging skin care brands. I look forward to working with Kathy Ireland and Kevin Harrington to help guide the launch of a consumer skin care line and infomercial retail launch.”
Mr. Schwarz most recently served as President of Sienna Labs where he co-developed the business plan to bring to market topical solutions based on plasmonic resonance for treatment of both aesthetic and disease based dermatological indications. Sienna labs recently completed $34 million Series A financing led by ARCH Venture Partners.
NuGene Co-Founder Ali Kharazmi said, “Ted is a well-known, visionary leader who was directly responsible for the successful exit of SkinMedica to multi-billion dollar Allergan for $350MM. I look forward to working with him to increase NuGene’s market share.”
“The Board of Directors unanimously agreed that Ted’s unparalleled track record makes him a must add for NuGene at this time of enormous opportunity,” said Saeed Kharazmi, M.D., CFO and member of the Board of Directors.
Mr. Schwarz received his BA degree in Marketing and Business from Michigan State University. His background also includes 15 years of Pharmaceutical executive sales and marketing leadership at Galderma and La Roche-Posay, a L’Oreal company.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.